The drug resistant virus treatment market size has grown strongly in recent years. It will grow from $9.42 billion in 2025 to $10.28 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited antiviral drug diversity, emergence of hiv and hepatitis drug resistance cases, reliance on single mechanism antiviral therapies, growth of global viral outbreak monitoring systems, increased hospital based infectious disease treatment protocols.
The drug resistant virus treatment market size is expected to see strong growth in the next few years. It will grow to $14.69 billion by 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expansion of precision antiviral therapy development, rising prevalence of multi drug resistant viral strains, increased investment in monoclonal antibody research, growth of genomic based resistance tracking, expansion of global pandemic preparedness programs. Major trends in the forecast period include next generation antiviral drug combination therapy adoption, broad spectrum antiviral resistance inhibitor development, personalized viral resistance profiling diagnostics, adaptive clinical trial designs for resistant viral strains, monoclonal antibody based rescue therapy expansion.
The increasing prevalence of antiviral drug resistance is anticipated to propel the growth of the drug-resistant virus treatment market coming years. Antiviral drug resistance is the ability of a virus to mutate and survive despite treatment with antiviral medications, reducing the drug’s effectiveness. Antiviral drug resistance is rising due to the rapid mutation rates of viruses, which enable them to quickly develop resistance to existing treatments. Drug-resistant virus treatments are used in antiviral drug resistance by employing alternative or combination antiviral therapies that target different viral mechanisms to suppress strains that no longer respond to standard drugs. For instance, in November 2025, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that without mitigation measures, HIV drug resistance to Dolutegravir (DTG) is projected to rise sharply among those failing DTG-based ART, increasing from 18% in 2023 to 42% by 2035. Therefore, the increasing prevalence of antiviral drug resistance is driving the growth of the drug-resistant virus treatment market.
Leading companies operating in the drug resistant virus treatment market are focusing on developing innovative therapies such as twice yearly long acting capsid inhibitor prophylactics to improve adherence and provide sustained protection against drug-resistant viral infections. Twice-yearly long-acting capsid inhibitor prophylactics are injectable antiviral therapies that target the viral capsid to block replication over an extended period, helping patients maintain viral suppression and prevent drug-resistant infections with just two doses per year. For example, in June 2025, Gilead Sciences Inc., a US-based biopharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Yeztugo (lenacapavir), a twice-yearly long-acting HIV-1 capsid inhibitor indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly PrEP option approved in the United States. Yeztugo is composed of lenacapavir, which inhibits the HIV capsid protein crucial for viral assembly and replication, and is administered as two subcutaneous injections that provide up to six months of protection, offering the key benefits of extended dosing intervals, high efficacy in clinical trials (≥ 99.9% protection), and improved adherence compared with daily oral PrEP regimens such as FTC/TDF.
In January 2026, Merck & Co. Inc., a US-based healthcare technology company, acquired Cidara Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Merck & Co., Inc. aims to reinforce and diversify its respiratory portfolio by advancing innovative antiviral therapies, accelerating the development of next-generation infectious disease treatments, and expanding its footprint in the fast-growing antiviral market to address unmet medical needs worldwide. Cidara Therapeutics Inc. is a US-based biotechnology company focused on developing long-acting antiviral therapies, including CD388, a potential first-in-class preventive treatment for influenza in high-risk populations.
Major companies operating in the drug resistant virus treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S. A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Vir Biotechnology Inc., Atea Pharmaceuticals Inc., Arbutus Biopharma Corporation, Chimerix Inc.
Asia-Pacific was the dominating region in the drug resistant virus treatment market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the drug resistant virus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug resistant virus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug resistant virus treatment market consists of revenues earned by entities by providing services such as diagnostic testing for resistant viral strains, personalized antiviral therapies, patient monitoring and management, medical consultation and clinical support, research and development of new drugs, preventive vaccination programs, and telemedicine or remote care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug resistant virus treatment market also includes sales of monoclonal antibodies, vaccines, diagnostic kits for resistance detection, rapid test kits, and supportive treatment products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug resistant virus treatment market size is expected to see strong growth in the next few years. It will grow to $14.69 billion by 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expansion of precision antiviral therapy development, rising prevalence of multi drug resistant viral strains, increased investment in monoclonal antibody research, growth of genomic based resistance tracking, expansion of global pandemic preparedness programs. Major trends in the forecast period include next generation antiviral drug combination therapy adoption, broad spectrum antiviral resistance inhibitor development, personalized viral resistance profiling diagnostics, adaptive clinical trial designs for resistant viral strains, monoclonal antibody based rescue therapy expansion.
The increasing prevalence of antiviral drug resistance is anticipated to propel the growth of the drug-resistant virus treatment market coming years. Antiviral drug resistance is the ability of a virus to mutate and survive despite treatment with antiviral medications, reducing the drug’s effectiveness. Antiviral drug resistance is rising due to the rapid mutation rates of viruses, which enable them to quickly develop resistance to existing treatments. Drug-resistant virus treatments are used in antiviral drug resistance by employing alternative or combination antiviral therapies that target different viral mechanisms to suppress strains that no longer respond to standard drugs. For instance, in November 2025, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that without mitigation measures, HIV drug resistance to Dolutegravir (DTG) is projected to rise sharply among those failing DTG-based ART, increasing from 18% in 2023 to 42% by 2035. Therefore, the increasing prevalence of antiviral drug resistance is driving the growth of the drug-resistant virus treatment market.
Leading companies operating in the drug resistant virus treatment market are focusing on developing innovative therapies such as twice yearly long acting capsid inhibitor prophylactics to improve adherence and provide sustained protection against drug-resistant viral infections. Twice-yearly long-acting capsid inhibitor prophylactics are injectable antiviral therapies that target the viral capsid to block replication over an extended period, helping patients maintain viral suppression and prevent drug-resistant infections with just two doses per year. For example, in June 2025, Gilead Sciences Inc., a US-based biopharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Yeztugo (lenacapavir), a twice-yearly long-acting HIV-1 capsid inhibitor indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly PrEP option approved in the United States. Yeztugo is composed of lenacapavir, which inhibits the HIV capsid protein crucial for viral assembly and replication, and is administered as two subcutaneous injections that provide up to six months of protection, offering the key benefits of extended dosing intervals, high efficacy in clinical trials (≥ 99.9% protection), and improved adherence compared with daily oral PrEP regimens such as FTC/TDF.
In January 2026, Merck & Co. Inc., a US-based healthcare technology company, acquired Cidara Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Merck & Co., Inc. aims to reinforce and diversify its respiratory portfolio by advancing innovative antiviral therapies, accelerating the development of next-generation infectious disease treatments, and expanding its footprint in the fast-growing antiviral market to address unmet medical needs worldwide. Cidara Therapeutics Inc. is a US-based biotechnology company focused on developing long-acting antiviral therapies, including CD388, a potential first-in-class preventive treatment for influenza in high-risk populations.
Major companies operating in the drug resistant virus treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S. A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Vir Biotechnology Inc., Atea Pharmaceuticals Inc., Arbutus Biopharma Corporation, Chimerix Inc.
Asia-Pacific was the dominating region in the drug resistant virus treatment market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the drug resistant virus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug resistant virus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug resistant virus treatment market consists of revenues earned by entities by providing services such as diagnostic testing for resistant viral strains, personalized antiviral therapies, patient monitoring and management, medical consultation and clinical support, research and development of new drugs, preventive vaccination programs, and telemedicine or remote care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug resistant virus treatment market also includes sales of monoclonal antibodies, vaccines, diagnostic kits for resistance detection, rapid test kits, and supportive treatment products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug Resistant Virus Treatment Market Characteristics
3. Drug Resistant Virus Treatment Market Supply Chain Analysis
4. Global Drug Resistant Virus Treatment Market Trends and Strategies
5. Drug Resistant Virus Treatment Market Analysis of End Use Industries
7. Global Drug Resistant Virus Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug Resistant Virus Treatment Total Addressable Market (TAM) Analysis for the Market
9. Drug Resistant Virus Treatment Market Segmentation
10. Drug Resistant Virus Treatment Market Regional and Country Analysis
11. Asia-Pacific Drug Resistant Virus Treatment Market
12. China Drug Resistant Virus Treatment Market
13. India Drug Resistant Virus Treatment Market
14. Japan Drug Resistant Virus Treatment Market
15. Australia Drug Resistant Virus Treatment Market
16. Indonesia Drug Resistant Virus Treatment Market
17. South Korea Drug Resistant Virus Treatment Market
18. Taiwan Drug Resistant Virus Treatment Market
19. South East Asia Drug Resistant Virus Treatment Market
20. Western Europe Drug Resistant Virus Treatment Market
21. UK Drug Resistant Virus Treatment Market
22. Germany Drug Resistant Virus Treatment Market
23. France Drug Resistant Virus Treatment Market
24. Italy Drug Resistant Virus Treatment Market
25. Spain Drug Resistant Virus Treatment Market
26. Eastern Europe Drug Resistant Virus Treatment Market
27. Russia Drug Resistant Virus Treatment Market
28. North America Drug Resistant Virus Treatment Market
29. USA Drug Resistant Virus Treatment Market
30. Canada Drug Resistant Virus Treatment Market
31. South America Drug Resistant Virus Treatment Market
32. Brazil Drug Resistant Virus Treatment Market
33. Middle East Drug Resistant Virus Treatment Market
34. Africa Drug Resistant Virus Treatment Market
36. Drug Resistant Virus Treatment Market Competitive Landscape and Company Profiles
37. Drug Resistant Virus Treatment Market Other Major and Innovative Companies
41. Drug Resistant Virus Treatment Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Drug Resistant Virus Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug resistant virus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug resistant virus treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug resistant virus treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Virus Type: Human Immunodeficiency Virus Drug Resistant; Hepatitis B Virus Treatment Experienced; Cytomegalovirus Resistant Or Refractory; Influenza Resistant Strains; Herpes Simplex Virus Or Varicella Zoster Virus Acyclovir Resistant; Other Virus Types2) By Therapy Class: Small Molecule Antivirals; Long Acting Injectables; Monoclonal Antibodies; Host Targeted Therapies; Combination Regimens
3) By Treatment Setting: Outpatient; Inpatient; Specialty Infusion Centers
4) By Route Of Administration: Oral; Intravenous; Subcutaneous; Intramuscular
5) By End User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Human Immunodeficiency Virus Drug Resistant: First Line Resistance; Second Line Resistance; Multi Drug Resistance; Transmitted Drug Resistance; Acquired Drug Resistance2) By Hepatitis B Virus Treatment Experienced: Nucleoside Analogue Resistant; Lamivudine Resistant; Entecavir Resistant; Tenofovir Partial Response; Multi Drug Resistant Hepatitis B
3) By Cytomegalovirus Resistant Or Refractory: Ganciclovir Resistant; Foscarnet Resistant; Cidofovir Resistant; Multi Drug Resistant Cytomegalovirus; Refractory Cytomegalovirus Infection
4) By Influenza Resistant Strains: Neuraminidase Inhibitor Resistant; Adamantane Resistant; Oseltamivir Resistant; Zanamivir Reduced Susceptibility; Multi Drug Resistant Influenza
5) By Herpes Simplex Virus Or Varicella Zoster Virus Acyclovir Resistant: Acyclovir Resistant Herpes Simplex; Acyclovir Resistant Varicella Zoster; Foscarnet Resistant Herpes Virus; Cidofovir Resistant Herpes Virus; Multi Drug Resistant Herpes Virus
6) By Other Virus Types: Respiratory Syncytial Virus Resistant; Adenovirus Resistant; Enterovirus Resistant; Norovirus Resistant; Emerging Viral Resistant Infections
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca plc; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Gilead Sciences Inc.; Regeneron Pharmaceuticals Inc.; Moderna Inc.; BioNTech SE; Alnylam Pharmaceuticals Inc.; Enanta Pharmaceuticals Inc.; Vir Biotechnology Inc.; Atea Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Chimerix Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug Resistant Virus Treatment market report include:- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- AbbVie Inc.
- Sanofi S.A.
- Novartis AG
- AstraZeneca plc
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences Inc.
- Regeneron Pharmaceuticals Inc.
- Moderna Inc.
- BioNTech SE
- Alnylam Pharmaceuticals Inc.
- Enanta Pharmaceuticals Inc.
- Vir Biotechnology Inc.
- Atea Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Chimerix Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | July 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.28 Billion |
| Forecasted Market Value ( USD | $ 14.69 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
